Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Executive Summary
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
You may also be interested in...
Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8
Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8
Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments
The key to successful use of targeted oncologic therapies will be routine genetic testing for both the patient and the tumor, Fox Chase Cancer Center Senior VP Robert Ozols suggested at an American Society of Clinical Oncology briefing Dec. 2